Table II.
Least Squares Mean SeSBP and SeDBP Reductions at Weeks 2, 4, 8, and 12 (Last Observation Carried Forward for Weeks 4, 8, and 12) and BP Goal Rates at Weeks 4, 8, and 12
| Olmesartan Medoxomil | Losartan Potassium | Valsartan | Placebo | |
|---|---|---|---|---|
| Week 2 | (n=199) | (n=200) | (n=197) | (n=100) |
| BP changes, mm Hg (90% CI) | ||||
| ΔSeSBP | −12.9 (−14.2 to −11.5)*†‡ | −8.5 (−9.8 to −7.1)* | −9.3 (−10.7 to −8.0)* | −4.5 (−6.3 to −2.6) |
| ΔSeDBP | −10.2 (−11.1 to −9.3)* ‡§ | −8.2 (−9.1 to −7.3)* | −7.9 (−8.8 to −7.0)* | −5.9 (−7.2 to −4.7) |
| BP goals, % achieving | ||||
| <140/90 mm Hg | 22.1* | 17.5* | 14.7* | 7.0 |
| <130/85 mm Hg | 7.0*§ | 2.5 | 3.0 | 0.0 |
| BP goals, % not achieving | ||||
| SBP ≥140 or DBP ≥90 mm Hg | 77.9 | 82.5 | 85.3 | 93.0 |
| SBP ≥130 or DBP ≥85 mm Hg | 93.0 | 97.5 | 97.0 | 100.0 |
| Week 4 | ||||
| BP changes, mm Hg (90% CI) | (n=199)|| | (n=200)|| | (n=197)|| | (n=100)|| |
| ΔSeSBP | −13.5 (−14.9 to −12.1)*†‡ | −9.6 (−11.0 to −8.2)* | −10.6 (−12.0 to −9.2)* | −4.2 (−6.1 to −2.3) |
| ΔSeDBP | −10.6 (−11.7 to −9.6)* ‡§ | −9.1 (−10.2 to −8.1)* | −9.2 (−10.2 to −8.2)* | −6.7 (−8.0 to −5.4) |
| BP goals, % achieving | (n=190)¶ | (n=194)¶ | (n=191)¶ | (n=97)¶ |
| <140/90 mm Hg | 27.4* | 20.6* | 22.0* | 10.3 |
| <130/85 mm Hg | 11.6! * | 6.2 | 5.2 | 4.1 |
| BP goals, % not achieving | ||||
| SBP ≥140 or DBP ≥90 mm Hg | 72.6 | 79.4 | 78.0 | 89.7 |
| SBP ≥130 or DBP ≥85 mm Hg | 88.4 | 93.8 | 94.8 | 95.9 |
| Week 8 | ||||
| BP changes, mm Hg (90% CI) | (n=189)|| | (n=192)|| | (n=189)|| | (n=94)|| |
| ΔSeSBP | −15.2 (−16.7 to −13.7)*† | −10.9 (−12.4 to −9.4)* | −13.0 (−14.5 to −11.4)* | −6.1 (−8.2 to −4.0) |
| ΔSeDBP | −12.9 (−13.9 to −11.8)*† | −9.4 (−10.4 to −8.3)* | −11.6 (−12.7 to −10.6)* | −6.9 (−8.3 to −5.5) |
| BP goals, % achieving | (n=184)¶ | (n=187)¶ | (n=183)¶ | (n=89)¶ |
| <140/90 mm Hg | 39.7*†‡ | 19.8 | 29.0* | 12.4 |
| <130/85 mm Hg | 14.7*§ | 7.0* | 13.1* | 1.1 |
| BP goals, % not achieving | ||||
| SBP ≥140 or DBP ≥90 mm Hg | 60.3 | 80.2 | 71.0 | 87.6 |
| SBP ≥130 or DBP ≥85 mm Hg | 85.3 | 93.0 | 86.9 | 98.9 |
| Week 12 | ||||
| BP changes, mm Hg (90% CI) | (n=182)|| | (n=180)|| | (n=181)|| | (n=87)|| |
| ΔSeSBP | −13.9 (−15.6 to −12.1)* | −13.4 (−15.2 to −11.7)* | −14.8 (−16.5 to −13.1)* | −4.4 (−6.8 to −2.0) |
| ΔSeDBP | −11.7 (−12.8 to −10.5)* | −11.5 (−12.7 to −10.4)* | −12.4 (−13.5 to −11.3)* | −5.7 (−7.2 to −4.2) |
| BP goals, % achieving | (n=170)¶ | (n=177)¶ | (n=180)¶ | (n=86)¶ |
| <140/90 mm Hg | 35.3* | 33.3* | 30.6* | 10.5 |
| <130/85 mm Hg | 18.2* | 11.3* | 11.1* | 2.3 |
| BP goals, % not achieving | ||||
| SBP ≥140 or DBP ≥90 mm Hg | 64.7 | 66.7 | 69.4 | 89.5 |
| SBP ≥130 or DBP ≥85 mm Hg | 81.8 | 88.7 | 88.9 | 97.7 |
| BP indicates blood pressure; CI, confidence interval; SeSBP, seated cuff systolic BP (SBP); and SeDBP, seated cuff diastolic BP (DBP). *P<.05 vs placebo. †P<.001 vs losartan potassium. ‡P<.05 vs valsartan. §P<.05 vs losartan potassium. ||The number of patients in the intent‐to‐treat efficacy cohort, using last observation carried forward for weeks 4, 8, and 12 (when the week 4, 8, or 12 value was missing, the week 2, 6, 10, or early termination value at the same dose level was substituted for the missing observation, respectively). ¶The number of patients with available observations at the visit. | ||||